Felix Rosenow studied medicine at the Free University of Berlin, did his residency training at the University of Cologne interrupted by a MD thesis stipend at the Max-Planck-.Institute for Neurological Research Cologne. He received postgraduate training at the Department of Neurology, Section of Epilepsy and Sleep disorders of the Cleveland Clinic Foundation. He subsequently established the Epilepsy Center Hessen at the Philipps-University Marburg and since 2015 is Director of the Epilepsy Center Frankfurt Rhine-Main.
He published more than 200 articles in pear review medical journals and is a member of the executive board of the DGKN (German Society of Clincal Neurophysiology and Functional Imaging) and of the Committee for evidence based epilepsy surgery of the ILAE. Previously (2005-17) her served as secretary of the trinational (Austria, Gemany, Switzerland) Working on presurgical epilepsy diagnosis of and operative epilepsy treatment.
Grants obtained since 2013:
- EpilepsieNetz Hessen (Telemedine network project), Funded through the Hessian Ministries of Social Affairs and Integration and of Research and Art’s LOEWE initiative. Total funding 750.000 €, 2018 – 2021,
- Center for Personalized Translational Epilepsy Research (CePTER) Funded through the Hessian Ministry of Research and Art’s LOEWE initiative. Total funding 4.7 Mio €, 2018 – 2021,
- EpimiRNA consortium (www.epimirna.eu): Funded through the European Union’s Seventh Framework Programme (FP7), Grant Agreement no. 602130. Total funding: 11.5 Mio €, Philipps-University Marburg 3 Mio €, 2013 –
Blumcke I,….Rosenow F, et al. Histopathological Findings in Brain Tissue Obtained from Epilepsy Surgery. New Engl J Med, 2017 377(17):1648-1656.
Baulac M, Rosenow F, et al . Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly-diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol, 2017;16(1):43-54
Reschke CR, …Rosenow F, Henshall DC. Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy. Mol Ther Nucleic Acids 2017;6:45-56
Rajman M, …Rosenow F et al. A microRNA-129-5p/Rbfox crosstalk coordinates homeostatic downscaling of excitatory synapses. The EMBO Journal, 2017 DOI 10.15252/embj.201695748
Raoof R, … Rosenow F, et al. Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus. Scientific Reports 2017 12;7(1):3328.
Pérez-Palma E, …Rosenow F et al. Heterogeneous contribution of microdeletions in the development of common generalised and focal epilepsies. J Med Genet. 2017 Sep;54(9):598-606.(IF 5,45)
Johannesen K, … Rosenow F, et al. Phenotypic spectrum of GABRA1: From generalized epilepsies to severe epileptic encephalopathies. Neurology, 2016;87(11):1140-51
Henshall DC,…. Rosenow F. MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol, 2016;15(13):1368-76
Helbig I, … Rosenow F, et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nature Genetics, 2009;41:160-2
Rosenow F, Lüders H. Presurgical evaluation of epilepsy. Brain, 2001;124: 1683-1700
Personalized translational epilepsy research, The role of micro-RNA in pathophysiology and treatment and as biomarker of epilepsy, epilepsy genetics, clinical epileptology, health economic assessment of epilepsy and status epilepticus.
About Epilepsy Centre Frankfurt Rhein-Main
The Epilepsy Center Frankfurt Rhine-Main is a comprehensive epilepsy center providing care for patients of all age groups and including all diagnostic and therapeutic options including for instance MEG, stereo-EEG and epilepsy surgery.
The team is also quite active in epilepsy related research. Felix Rosenow is the Co-Coordinator of the EU (FP7) financed project Epimirna and partner of CePTER: Center for Personalized Translational Epilepsy Research funded by the state of Hesse from 2018-21.
The center’s reseach activities are also supported by the Detlev-Wrobel-Fonds for Epilesy Research and the Uniscientia Foundation. Recently the TSC Center Frankfurt was established to provide better care for patients with the rare condition of tuberous sclerosis.